Breaking Finance News

Zacks Investment Research covered Glaukos Corp (NYSE:GKOS), raising its target price to $44.00 today

Having a price of $38.33, Glaukos Corp (NYSE:GKOS) traded -0.39% lower on the day. With the last close up 38.96% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Glaukos Corp has recorded a 50-day average of $33.96 and a two hundred day average of $27.58. Volume of trade was down over the average, with 429,165 shares of GKOS changing hands under the typical 519,205

Glaukos Corp (NYSE:GKOS) had its stock price target increased to $44.00 by Zacks Investment Research in a report released 10/05/2016. The new stock price target indicates a potential upside of 0.15% from the company's most recent close.

Performance Chart

Glaukos Corp (NYSE:GKOS)

With a total market value of $0, Glaukos Corp has with a one year low of $14.25 and a one year high of $39.82 .

A total of 6 analysts have released a research note on Glaukos Corp. Two analysts rating the company a strong buy, three analysts rating the company a buy, two analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $31.00.

More About Glaukos Corp (NYSE:GKOS)

Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye's anterior chamber through a corneal incision. The Company's micro-scale injectable therapies include pipeline products, such as the iStent Inject, the iStent Supra and iDose. The iStent Inject includes approximately two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *